Genetic epidemiology, including twin studies, provides robust evidence that genetic variation in human populations contributes to susceptibility to infectious disease. One of the major limitations of studies that attempt to identify the genes and mechanisms that underlie this susceptibility has been lack of power caused by small sample size. With the development of novel technologies, burgeoning information on the human genome, the HapMap project, and human genetic diversity, we are at the beginning of a new era in the study of the genetics of complex diseases. This review looks afresh at the epidemiological evidence that supports a role for genetics in susceptibility to infectious disease, examines the somewhat limited achievements to date, and discusses current advances in methodology and technology that will potentially lead to translational data in the future.
Introduction
Infection is one of the leading causes of human mortality and morbidity, with much of the burden falling on children. 1 Infectious diseases are a major selective pressure, [2] [3] [4] [5] and the genes involved in the immune response are the most numerous and diverse in the human genome, 6 indicating the evolutionary advantages of a varied immunological response to a wide range of infectious pathogens.
7 This is most obvious at the HLA loci, 8 the prototypical candidate genetic region for infectious disease susceptibility. For example, individuals in whom all class II HLA alleles are heterozygous are more likely to clear hepatitis B infection, 9 and those with heterozygous class I alleles progress from HIV to an AIDS-defi ning illness more slowly and have lower mortality. 10 The converse scenario, increased HLA homozygosity, may contribute to the increased susceptibility to infection in genetically isolated populations. 11 There is huge variation in the individual outcomes that follow exposure to potentially life-threatening pathogens, and this diff erential susceptibility partly shows the functional genetic diversity of the immune response. Here we provide an overview of human genetic susceptibility in infectious diseases, review the supporting epidemiological evidence, discuss current methodological and technological issues, and highlight the somewhat limited achievements to date, especially those that have increased our understanding of outcome and treatment response for specifi c infectious diseases.
One gene…or many?
Susceptibility to infection and many other human diseases (including diabetes and ischaemic heart disease) arises from the complex interaction of environmental and host genetic factors. In general, many genetic loci make modest contributions to human disease susceptibility (ie, they are genetically complex), and most of the focus in the fi eld has been on identifying these loci and their eff ects in infection and in other conditions. However, there are many singlegene (Mendelian) disorders aff ecting immune function, with over 300 primary immunodefi ciencies reported. Although often rare, these profound immunodefi ciencies stem from major functional aberrations at single genes and can be highly informative about immunological mechanisms and protection against specifi c infections. 12, 13 There are also important examples of more common single-gene disorders that markedly infl uence infectionspecifi c susceptibility; the best known is the protection aff orded by sickle cell heterozygosity against falciparum malaria.
14 A variant in the Duff y antigen gene promoter, which results in lack of erythrocyte surface expression, prevents binding by Plasmodium vivax, and is therefore protective. 15, 16 More recently, a genetic variant that determines blood group secretor status has been shown to mediate susceptibility to Norwalk virus, 17 and also to aff ect HIV progression independently of other chemokine variants. 18 
Hype and hyperbole
There has been substantial expectation that an increased understanding of the genetic determinants of diff erential susceptibility and outcome would be rapidly translated into novel therapies and preventative interventions. Much of this expectation has yet to be realised, partly because of the methodological limitations of earlier studies and a tendency to examine individual genes in isolation and without consideration of their genetic and environmental milieu. Thus many reported genetic associations have not been replicated in subsequent studies. 19 Understandably, some scepticism exists as to how much a genetic epidemiological approach can actually reveal about the genetic basis of complex diseases. 20 However, there have been many recent advances in technology and-more latterly-its application; such studies have identifi ed important protective and pathogenic pathways, and have led to individually targeted anti-infective therapies. Hopefully, we are entering an era in which well designed studies will begin to deliver robust genetic data and many more opportunities for translation into better treatments.
Epidemiological evidence
The idea that human genetics may contribute to our understanding of the susceptibility to infectious Review diseases is not new. As early as the 18th century, diff erential susceptibility to infection was suggested to be a characteristic of the host, and diseases such as tuberculosis and leprosy were believed to be inherited defects. 21 Infectious diseases, like other phenotypes, may exhibit familial aggregation: a greater frequency of the disease in relatives of infected individuals compared with relatives of those without disease. Studies of familial aggregation can therefore investigate the importance of shared determinants, both environmental and genetic, in disease susceptibility. They usually use a form of the recurrence risk ratio, essentially the ratio of prevalence in the relatives of the index case to the prevalence in the general population. It is important in such studies that the disease phenotype is carefully defi ned, particularly in the context of infectious diseases. Interpretation of recurrence risk is more straightforward if the phenotype is a binary or dichotomous trait (eg, the presence or absence of meningococcal septicaemia) than a qualitative range of clinical phenotypes, which may be less consistent (eg, measures of severity of infection determined by treatment interventions). Familial aggregation measures make no supposition about the cause of such aggregation, and recurrence risks within the same generation, such as sibling risk ratios, will identify both shared environmental and genetic eff ects. In infectious diseases, transmission of pathogens between family members may increase the risk of disease and contribute to the observed phenotypic aggregation. For example, in a study of sibling recurrence risk ratio for meningococcal disease, there was a 30 times increased risk of infection in siblings of cases compared with the general population risk, but the risk decreased with a longer time interval between the index case and the sibling case. 22 The recurrence risk for meningococcal disease in siblings was 11·9 times the population risk when the index and sibling cases occurred more than a week apart, falling to a risk of 8·2 if a year had elapsed between cases. 22 These data indicate signifi cant genetic determinants of meningococcal susceptibility, and also the importance of common acquisition of virulent strains within families, which accounts for the more immediate increased risk in household contacts. 23 
Twin studies
Studies of twins can also provide an estimate of the relative contributions of shared genes and environment to disease phenotypes, by comparing the risk in genetically identical monozygotic twin pairs to that in dizygotic twins, who share on average only half their genes. Some twin studies of infectious diseases are historical, [24] [25] [26] and determinations of zygosity and disease phenotype may be inaccurate. 25 Notwithstanding these reservations, susceptibility to some infections show markedly increased concordance in monozygotic compared with dizygotic twins. 27 Examples include tuberculosis, [24] [25] [26] sinusitis, 28 Helicobacter pylori-specifi c antibody titres, 29 and leprosy. 30 More recent twin and triplet data indicate that susceptibility to both acute and chronic otitis media is largely genetically determined. 31, 32 The relative contributions of infection, atopy, and craniofacial anatomy, all of which are determined in part by genetic factors, remain unclear.
Twin studies may also provide useful insights into the determinants of disease outcome. Carrier status for hepatitis B virus 33 and the febrile response to (but not acquisition of) Plasmodium falciparum 34 both indicate increased concordance in monozygotic twin pairs. A study of the severity of common childhood infections, which used hospital admission as the phenotype, indicated that distinct genetic factors were likely to be involved in diff erent infections, since the risk of admission in the second twin was only increased if the twins both had the same infectious diagnosis (Burgner D, unpublished). The concordance rates for common otolaryngological procedures such as myringotomy and adeno-tonsillectomy, which are surrogates for disease severity, also show greatly increased concordance in monozygotic twin pairs (Burgner D, unpublished). Twin studies of vaccine responses, in which the antigenic stimulus is unambiguous, indicate signifi cant genetic infl uences on both humoral 35 and cellmediated 36 responses. More detailed genetic studies indicate the importance of both HLA and non-HLA loci in vaccine responsiveness. 37, 38 Studies in vitro of twins 39 and fi rst-degree relatives 40 also show the importance of genetic factors in determining the innate immune responses to infectious stimuli.
A twin study of H pylori acquisition, which compared concordance rates for twins reared either together or apart, gave very similar measures of genetic infl uences in each setting, which accounted for most of the disease risk. 29 However, twins and siblings are very commonly reared together, making it diffi cult to tease out the relative contributions of genetic factors and shared environ mental exposures, particularly pathogen sharing. Intergenerational studies may circumvent this issue. A seminal study compared the risk and shared causes of premature mortality in children adopted very early in life with that of their biological and adoptive parents. 41 The risk of an adopted child dying of infection was increased almost six times if their biological parent had also died prematurely of infection, whereas no increased risk was observed if the adoptive parent died of infection, suggesting that genetic rather than environmental factors are the important determinants of infectious disease mortality. Much smaller genetic eff ects were noted for cardiovascular disease and malignancy. 41 
Study design and methodological issues
These epidemiological data indicate that genetic factors infl uence both susceptibility to, and outcome of, Review infection. The various study designs and methodological issues are important in interpreting previous data and in designing contemporary and future studies in infection. As the fundamentals of genetic epidemiology have recently been reviewed in detail, [42] [43] [44] [45] [46] [47] [48] only a brief overview will be provided here. Some of the terminology is explained briefl y in the panel. Of note, although single nucleotide polymorphisms (SNPs) are the workhorse of current high-throughput genotyping technologies, other forms of genetic variation are also common in the human genome and may have important eff ects on disease risk. These include repeating sequence motifs (microsatellites and minisatellites), insertions and deletions, and diff erences in gene copy number. 55 For example, recent data indicate that there is a strong inverse correlation between the number of copies of an HIV suppressive chemokine gene (CCL3L1) and HIV susceptibility. 
Genome-wide linkage and association studies
There are essentially two types of study design-genomewide and candidate gene-that are used to localise the genes underlying human disease. Genome-wide studies have the advantage that no supposition is made about the genes involved, and potentially novel or unconsidered genes may be identifi ed. Typically, the genome-wide approach has used linkage studies of multiply aff ected (or infected) pedigrees to identify regions of the entire genome that are transmitted from the parents to the off spring more often than expected under independent inheritance. 43 Typically, aff ected sibling pairs, 57, 58 or larger multicase pedigrees 59 if available, are recruited and the inherited regions of the genome are defi ned by a few hundred microsatellite markers. The main disadvantages of linkage studies are that suffi cient numbers of aff ected sibling pairs may be diffi cult to recruit for many infections, and that linkage studies are often too insensitive to pick up the relatively small contributions from individual genetic regions that are typical of complex diseases such as infection. There are examples of successful genome scans undertaken using linkage analysis for infectious diseases, including the intensity of infection with Schistosoma mansoni, 59 susceptibility to H pylori, 60 and to leprosy. 57, 58, 61 As with association data, some linkage studies have not been replicated in diff erent populations. In some cases this may represent a false discovery rate, an inherent problem in studies that make multiple statistical comparisons, but it is increasingly clear that many complex diseases show genetic heterogeneity, with diff erent genetic determinants for the same disease operating in diff erent ethnic groups. For example, mutations in the NOD2/CARD15 locus, an important susceptibility determinant of infl ammatory bowel disease in white populations, are eff ectively absent in Asian populations with the same phenotype. 62 Genome-wide association studies, in which the whole genome is interrogated using hundreds of thousands of SNPs, have recently become a reality as genotyping technology and analytical tools evolve. This approach will potentially detect more subtle genetic eff ects than a classic linkage study. 63 At present, studies use up to 0·5 million of the approximately 11 million estimated SNPs in the human genome, but there are unresolved
Panel: Defi nitions for genetic terminology
Allelic association Statistical analysis to determine whether disease is associated with particular allelic variants at one or more loci, usually by comparing marker allele frequencies between a disease group and a control group.
F ST statistic A statistic to describe individuals, subpopulations, and whole population structures. Used to assess evidence for selection by comparing the frequency of an allele in diff erent populations.
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Haplotype A combination of marker alleles at diff erent markers along the same chromosome that tend to be inherited as a unit.
Haplotype tag
An SNP that acts as a defi ning marker for a haplotype by virtue of linkage disequilibrium. Analysing haplotype tags, rather than all the variants on a haplotype, reduces redundancy and genotyping costs.
Heterozygosity
A measure of genetic diversity within a population.
Linkage analysis
Statistical analysis to localise genes and markers with respect to each other in the genome, based on recombination frequency. Linkage analysis can also be used to map a disease phenotype in relation to polymorphic markers.
Linkage disequilibrium
The non-random association of alleles at two or more neighbouring loci that are inherited together more often than expected by chance, providing the basis to haplotypes and linkage disequilibrium mapping. This association can potentially derive from population admixture.
Microsatellite
A polymorphism characterised by a variable number of tandem repeats, often defi ned by the numbers of repeats in a row of at least two or more nucleotides. They are useful markers for family linkage studies and determining a person's unique DNA fi ngerprint in forensic medicine. Also known as SSR (simple sequence repeat) or STR (simple tandem repeat).
Population admixture
The recent combination of two or more previously distinct populations. Unknown admixture may result in spurious genetic associations in a case-control study design.
SNP
Single nucleotide polymorphism, single base-pair change at a specifi c point in the genome.
SNP chip
Array technology that allows large numbers (up to a million) of SNPs to be genotyped on a single array typically the size of a microscope slide (eg, Aff ymetrix 50 Review issues particularly relating to the optimum density and location for these SNP markers (gene-centric or evenly spaced through the genome), which have implications for how much of the genome such studies truly cover, 45 as well as concerns regarding sample size and power. 64 Genome-wide association studies have a high false discovery rate, and replication in independent populations is essential. There are currently no reported genomewide association studies in infectious diseases, although such studies are underway. In particular, studies being undertaken under the banner of the Wellcome Trust Case-Control Consortium will look at up to 2000 cases and 3000 controls for eight complex diseases, including tuberculosis and malaria. 65 For these two important infectious diseases, a two-stage strategy is proposed in which a 750 000 SNP chip (panel) will be used to genotype 1000 cases and 1000 controls, and regions positive at p=0·1 followed up in at least another 1000 cases and 1000 controls. This is one of the biggest projects ever undertaken to identify the genetic variations that may predispose people to, or protect them from, complex diseases. The hope is that by identifying these genetic signposts, researchers will be able to understand which people are most at risk, and also produce more eff ective treatments.
The genome-wide association approach has been used on a smaller scale in other non-infectious genetically complex diseases. For example, genotyping of almost 93 000 SNPs across the genome has identifi ed a region of chromosome 6 associated with myocardial infarction. Further mapping identifi ed a novel functional polymorphism in the lymphotoxin alpha (LTA) gene within this region and related functional variants in a ligand of LTA. 66, 67 The odds ratio associated with the LTA mutation was 1·78, 67 an order of magnitude expected for a complex disease. In another study, a 120 000 SNP chip was used to compare 96 cases of age-related macular degeneration with 50 controls to identify a major gene (complement factor H) that determines susceptibility. 68 A common intronic SNP among the 120 000 SNPs genotyped was strongly associated with disease, with a nominal p value of less than 10 -7 (after correction for multiple testing), and a genotype relative risk for homozygous individuals of 7·4 (95% CI 2·9-19·0). Resequencing revealed a polymorphism in linkage disequilibrium with the risk allele that caused a tyrosine to histidine change at amino acid 402 in the complement factor H protein. The numbers of cases and controls studied was small, increasing the possibility of a false positive result (although the relative risk was high compared with our usual expectation for complex diseases). Importantly, the SNP-chip study was immediately supported by two studies using four independent case-control populations. 69, 70 These studies provide a major conceptual breakthrough in terms of the approaches that can be made with novel technologies, now more feasible with the recent publication of the phase I HapMap, 71 and the data for phase II released in 2005 (http://www.hapmap. org). The main practical objective of the HapMap project was to identify sets of SNPs that are in linkage disequilibrium with each other, so that a subset of these can be genotyped as so-called haplotype-tagging SNPs in a genome-wide association study, thus reducing the overall amount of genotyping required. The phase I data involved the genotyping of 1 million SNPs in unrelated individuals or parent/child trios of Nigerian, European, Chinese, and Japanese descent. Phase II extends this to 3·5 million SNPs. The phase I data has already provided many predictions and tests of applicability of haplotype tagging across populations, 72, 73 optimum sampling and two-stage testing strategies for whole genome association studies, 74 and which commercially available SNP chips will work best. As predicted from previous studies, a greater density of SNPs on a chip is required to capture all the haplotypic diversity in the African population compared with European, Chinese, or Japanese populations, because of the greater diversity and shorter regions of linkage disequilibrium observed in the former, 75 a factor that will be important in application of the technology to infectious disease association studies in Africa. Nevertheless, for 1000 cases and 1000 controls and a nominal p value of 0·01, the phase I HapMap (eg, the newly released Sentrix human Hap300 genotyping beadchip by Illimuna; 51 one SNP about every 12 kb) retains 77% power to detect associations due to common (≥5%) causal alleles in the African population, compared with roughly 90% in European, Chinese, or Japanese populations. 75 The 500 000 SNP chip from Aff ymetrix, 50 which was made before the release of phase I HapMap haplotype-tagging SNP information, has about the same power as the Illumina human Hap300 chip (ie, it contains about two tags per haplotype).
Candidate gene approach
Although there will probably be many whole genome association studies in the future, to date most studies of complex diseases, including infection, have adopted a candidate gene approach. The choice of the candidate genes may come from animal data, 76 ,77 results of wholegenome studies, 57, 58, 78 clinical data, 79, 80 or simply biological plausibility. Important methodological considerations in this approach include the following: (1) an adequate density of the markers in the candidate gene to ensure that the study has suffi cient sensitivity to exclude a genetic region; (2) narrow and consistent phenotypic defi nitions; (3) matching of cases and controls; and (4) sample size and power.
Most candidate gene studies use a case-control approach, and unrecognised ethnic diff erences between the groups will probably result in spurious genetic associations that are unrelated to the disease of interest. For example, there is probably a strong association Review between the HLA region and chopstick use in Sydney. This does not imply that the HLA region necessarily infl uences manual dexterity, but more likely that the HLA type identifi es an Asian subpopulation. This issue of population stratifi cation is likely to be more confounded when small genetic eff ects are sought in large populations. 81 However, this confounding can be minimised if cases and controls are carefully matched. The presence of genetic admixture can also be quantifi ed from the genetic data itself, 82 allowing stratifi ed analyses if the sample size permits. In paediatric populations, an alternative approach is to use the parents as the genetic controls for their aff ected off spring. 83 This approach is intrinsically less powerful than case-control designs, since the parental controls are enriched for the genetic variants of interest, but it allows inclusion of families of mixed ethnicity and potential pooling of data across ethnic groups, if signifi cant genetic heterogeneity is not present.
Probably the most crucial and overlooked methodological issue is sample size and power. Because the genetic eff ects from individual genetic variants are usually modest, the genetic model (mode of inheritance) is often unknown, and the frequency of the diseasemodifying variant may vary, almost all studies of complex disease genetics to date have been underpowered. Power calculations (fi gure) indicate that in excess of 1500 casecontrol pairs or case-parent trios are needed to provide adequate power, especially as eff ect sizes (odds ratios) expected for a genetic contribution to complex disease susceptibility will probably be small (about 1·5).
The lack of power owing to small sample sizes makes it diffi cult to interpret current and previous data on genetic susceptibility to infection. For this reason we have not attempted a critical appraisal or value judgment of past and present studies, but have provided comprehensive tables (webtables 1, 2, 3 and 4) that list all of the studies undertaken to date for the most commonly studied infectious diseases-HIV, mycobacterial infections (leprosy and tuberculosis), malaria, and leishmaniasis. Whereas some loci (eg, HLA class I, class II, and class III alleles, SLC11A1) feature repeatedly both within and between diseases, no formal meta-analyses 86 of these smaller studies have yet been undertaken to determine which may indicate statistically reliable associations. One interesting observation is the number of candidate gene studies that have focused on proteins involved in innate recognition of microbes and fi rst-line defence innate immunity pathways (table 1), underscoring the likely selective pressures that have been exerted by infectious diseases. The key genes that regulate acquired immune responses also feature as candidate genes in multiple infectious diseases (table 2) .
Most of these studies also suff er from a lack of statistical power, and require replication and validation. of these immune response genes are highly polymorphic or clustered, or both, in the genome, which is an indication of evolutionary pressure and selection. 166, 167 A more formal attempt to search for signals of evolutionary selection was Power to detect allelic association for a risk allele having an eff ect size (odds ratio) of 1·5 (A) 500, (B) 1500, and (C) 3000 trios or case-control pairs. Power is calculated for diff erent frequencies of risk alleles, and for samples of 500, 1500, or 3000 trios or case-control pairs. Power approximations for trios by a standard transmission disequilibrium test 84 have been made using the method of Knapp. 85 Theoretical power to detect allelic association was made assuming a multiplicative model. Results are given as a fi rst approximation of the percentage power to detect allelic association at p=0·01, p=0·001, or p=0·0001. Power calculations were essentially identical for a similar size case-control sample. The advantage of trios is that they are not infl uenced by population admixture. The advantage of case-control analysis is one third less genotyping to obtain equivalent power. The graphs show that 500 trios or case-control pairs have very poor power to detect allelic association even for relatively common risk alleles (frequencies >0·2). A sample of 1500 trios or case-control pairs has good power for risk alleles at frequencies >0·1. A sample of 3000 trios or casecontrol pairs improves power for rare risk alleles (frequencies <0·1).
See Online for webtables 1,2,3 and 4.
Review recently undertaken in 168 genes related to immune function. 3 Almost 1700 common SNPs were successfully genotyped across these genes in three population samples: 96 independent chromosomes from Utah residents with European ancestry, 120 from Han Chinese Guangxi, and 124 from the Yoruba people of Southwest Nigeria (these samples were overlapping but not identical to those used in the HapMap project). Evidence for selection was based on four tests of non-neutral evolution: (1) assessment of the percentage of SNPs within a locus with low (<10%) minor allele frequency and the percentage with high (>40%) minor allele frequency; (2) assessment of the frequency of derived (non-ancestral) alleles; (3) comparison of F ST (panel) versus heterozygosity; and (4) relative extended haplotype homozygosity. In tests of allele frequency, three of the 168 genes stood out: IL9, FUT2, and CAV2. IL9 lies in the cluster of T-helper-2 related genes encoding interleukins 4, 5, 9, and 13 on chromosome 5q31-q33, which has been implicated in many infectious disease studies (table 2; webtables 1-4). FUT2 encodes a protein responsible for determining ABO blood protein secretor status, and variation in this gene may protect against respiratory pathogens, 168 H pylori, 169 and HIV-1. 170 CAV2 encodes one of the caveolin proteins that function as scaff olding structures in cholesterol-rich lipid rafts, which enhance immune cell function, 168, 171 and are involved in pathogen entry into host cells. 172 The relative extended haplotype homozygosity test provided the best evidence for selection, highlighting ABCC1 (or multidrug resistance protein MRP1, implicated in resistance to Streptococcus pneumoniae in mice 173 ), APCS (serum amyloid P component), and VAV3 (a guanine nucleotide exchange factor expressed in haematopoietic and other cells, recently identifi ed as a gene for type I diabetes in mice 174 ) as genes with signatures of past selection. Although Walsh and colleagues 3 discuss the limitations of their study and the need for validation, their research pilots the search for signatures of evolutionary selection that can now be 
Gene-gene and gene-environment interactions
Genetic determinants obviously act in a genetic and environmental context, a fact often ignored in genetic epidemiological studies that have previously regarded the environment as something of an annoyance. A genetic variant may substantially increase the risk of avian infl uenza several hundred times, but if the person carrying the variant never encounters H5N1 infl uenza, or requires an additional polymorphism in a diff erent gene to have a functional eff ect, then this fi rst variant may be of no clinical relevance. The fi eld of genetic epidemiology is increasingly acknowledging the importance of complex biological interactions in understanding genetic determinants. Gene-gene interactions (epistasis) have been described for HIV infection, in which an HLA class I allele is associated with more rapid progression to AIDS only when an individual also carries a specifi c natural killer cell (KIR) receptor. 175 Gene-environment interactions have been shown in spontaneous preterm labour, which has an infl ammatory basis. Although genetic variation at the tumour necrosis factor (TNFA) gene is associated with increased risk of preterm labour, this risk is increased signifi cantly in the presence of bacterial vaginosis, itself an independent risk for the same outcome. 176 In cystic fi brosis, those carrying functional variants of mannosebinding lectin (MBL) have worse pulmonary outcomes, 177 and replacement MBL therapy has been reported in MBLdefi cient cystic fi brosis patients. 178 Not surprisingly, MBL exerts a protective eff ect through its innate immunological eff ects and in a recent small study, MBL defi ciency only aff ected lung function when associated with Staphylococcus aureus colonisation, 179 an example of a gene-enviroment interaction.
Conclusion: translation of genetic data into therapeutic interventions
Despite an increasing body of robust data identifying genetic determinants of infectious diseases and illuminating key biological pathways, the move from bench to bedside in infectious diseases and other fi elds remains largely an unrealised, but often made, prediction. There are a few worthy exceptions. Functional genetic variation of the P450 cytochrome system seems to mediate the effi cacy of H pylori eradication by its eff ects on proton pump inhibitor metabolism. 180 The most striking and elegant example of pharmacogenetics is in HIV medicine, in which hypersensitivity to the nucleoside reverse transcriptase inhibitor abacavir has previously limited its use. Analysis of the MHC led to the identifi cation of a particular HLA haplotype that greatly increased the risk of abacavir hypersensitivity, 181 and further mapping localised a functional variant in the peptide-binding groove of heat shock protein 70, which lies in the central MHC. 182 Genotyping individuals for this variant before commencing abacavir is cost eff ective. 183 Hopefully, further examples of clinically relevant pharmacogenetics in infectious diseases will be reported. In the face of increasing antimicrobial resistance, falling pharmaceutical enthusiasm for new antibiotic development, and the disappointing track record of adjunct biological therapies in severe sepsis, the development of novel vaccines and pharmacogenetic interventions remain among the most important goals for genetic studies of infectious disease susceptibility.
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Data for this review were identifi ed by searches of PubMed, MEDLINE, Current Contents, and references from relevant articles; numerous articles were identifi ed through searches of the extensive fi les of the authors. Search terms included combinations of "susceptibility", "genetic susceptibility", "heritability", "twin", "genetic", "genetic epidemiology", "infection", "infectious diseases", as well as terms for specifi c infections (eg, "malaria") and genes and gene products (eg, "mannose binding lectin"): eg, PubMed search term: "HIV AND polymorphism NOT drug"; fi eld: text word; limits: humans. No date or language restrictions were set in these searches.
